Skip to content
AI IntelligenceMar 29, 2026Secondary Market
Article

AGL

BTIG cuts its price target on Humacyte (HUMA) but maintains a Buy rating, citing a larger long-term opportunity despite near-term challenges. The stock movement reflects this mixed analyst sentiment.

Data Cube AI EditorialSource: Yahoo Finance
01

Source Brief

BTIG cuts its price target on Humacyte (HUMA) but maintains a Buy rating, citing a larger long-term opportunity despite near-term challenges. The stock movement reflects this mixed analyst sentiment.